Fig. 1 · Structure

Documents & Downloads

MifaMurtide

Cat. No. A12400 CAS 83461-56-7
Mifamurtide is a liposomal formulation containing a muramyl dipeptide (MDP) analogue with potential immunomodulatory and antineoplastic activities

In Stock

Publications for MifaMurtide

1 publication citing this product

  1. François A. Simard, .et al. , Oncoimmunology, 2017, 6(2): e1265716 PMID: 28344871

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
NOD2  

In Vitro Studies

Chronic treatment with MifaMurtide significantly increased RANK mRNA expression in MG63 monocultures compared with MG63 alone. In BMDMs undergoing RANKL- and M-CSF-induced differentiation, MifaMurtide significantly reduced mature osteoclasts, with their number inversely related to MifaMurtide concentration. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

RANK Expression in MG63 Monocultures

Cell-based study · Monocultures of MG63 [1]

MG63 monocultures treated chronically with MifaMurtide showed a significant increase in RANK mRNA expression compared with MG63 alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
RANK mRNA expression levelsReported result Monocultures of MG63 were also obtained and treated chronically with Mifamurtide [100 µM] for 7 days. Mifamurtide induced a significant increase of RANK expression in MG63 cells.[1]

Literature-Reported Treatment Conditions

Treatment concentration
100 µM
Exposure duration
treated chronically with Mifamurtide [100 µM] for 7 days
Method
used in culture
Vehicle
sterile water
Methods and source locations

Compound reported in the paper: MifaMurtide

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > Mifamurtide modulates osteoblast markers (S9); MATERIALS AND METHODS > Cell cultures (S24); MATERIALS AND METHODS > Drugs (S66); Figure 4 legend (S101, S103)

RANK mRNA expression levels: RANK mRNA expression levels; comparator: MG63 alone — RESULTS > Mifamurtide modulates osteoblast markers (S9); MATERIALS AND METHODS > Cell cultures (S24); Figure 4 legend (S101)

Osteoclast Differentiation in BMDMs

Cell-based study · BMDMs [2]

BMDMs undergoing osteoclast differentiation induced with RANKL and M-CSF were treated with different concentrations of MifaMurtide. Mature osteoclasts were significantly reduced, and their number was inversely related to MifaMurtide concentration.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Quantitative analysis of TRAP-positive MNCsReported result BMDMs were subjected to osteoclast full differentiation induced with RANKL (40 ng/ml) and M-CSF (10 ng/ml) for 5 days under different concentrations of mifamurtide (0, 50, 5000 nM). The results showed that mature osteoclasts were significantly reduced under the simulation of mifamurtide, and the concentration of mifamurtide was inversely proportional to the number of mature osteoclasts.[2]

Literature-Reported Treatment Conditions

Treatment concentration
0, 50, 5000 nM
Exposure duration
5 days
Co-treatment
Other interventions in this design: RANKL 40 ng/ml; M-CSF 10 ng/ml. Compound effect isolated by the comparison: different concentrations of mifamurtide (0, 50, 5000 nM).
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: MifaMurtide

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Pharmacological inhibition of Irgm1 alleviates OVX-induced osteoporosis (S220); Fig. 8 legend (S357, S359)

Quantitative analysis of TRAP-positive MNCs: Quantitative analysis of TRAP-positive MNCs; comparator: 0 nM — Results > Pharmacological inhibition of Irgm1 alleviates OVX-induced osteoporosis (S220); Fig. 8 legend (S357, S359)

In Vivo Studies

Mice received MifaMurtide through the tail vein after OVX. Micro-CT images showed significantly increased bone mass in the MifaMurtide group compared with the PBS group. [2]

Bone mass in mice after OVX

Animal study · mice [2]

Mice received MifaMurtide through the tail vein after OVX. Micro-CT images showed significantly increased bone mass in the MifaMurtide group compared with the PBS group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Micro-CT imagesReported result Mice treated with mifamurtide (1 mg/kg, i.v.) or PBS one week after OVX were sacrificed at 20-week-old. Micro-CT images showed the bone mass in the mifamurtide group was significantly increased compared with PBS group.[2]

Conditions shared by the study groups

Route
tail vein
Treatment course
one week after OVX; twice a week for 4 weeks.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
MifaMurtide 1 mg/kgPBS groupMice treated with mifamurtide (1 mg/kg, i.v.) or PBS one week after OVX were sacrificed at 20-week-old. Micro-CT images showed the bone mass in the mifamurtide group was significantly increased compared with PBS group.[2]
MifaMurtide 1 mg/kg
Model: mice
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: MifaMurtide

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Animals (S16); Results > Pharmacological inhibition of Irgm1 alleviates OVX-induced osteoporosis (S215, S216); Fig. 8 legend (S349)

Micro-CT images: Micro-CT images; comparator: PBS group — Results > Pharmacological inhibition of Irgm1 alleviates OVX-induced osteoporosis (S216); Fig. 8 legend (S349)

MifaMurtide 1 mg/kg · Materials and methods > Animals (S16); Results > Pharmacological inhibition of Irgm1 alleviates OVX-induced osteoporosis (S215, S216); Fig. 8 legend (S349)

Specifications

Manufacturer Adooq Bioscience
CAS Number 83461-56-7
Formula C59H109N6O19P
Molecular Weight 1237.5
Synonyms CGP 19835A Lipid; muramyl tripeptide phosphatidylethanolamine liposome; L-MTP-PE
SMILES
O=P(OCCNC([C@@H](NC(CC[C@@H](NC([C@@H](NC([C@H](O[C@@H]1[C@@H](NC(C)=O)[C@H](O)O[C@H](CO)C1O)C)=O)C)=O)C(N)=O)=O)C)=O)(O)OCC(OC(CCCCCCCCCCCCCCC)=O)COC(CCCCCCCCCCCCCCC)=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Punzo F, Bellini G, Tortora C, et al. Mifamurtide and TAM-like macrophages: effect on proliferation, migration and differentiation of osteosarcoma cells. Oncotarget (2020). PMID: 32133045 DOI: 10.18632/oncotarget.27479 Source material
  2. [2] Cui Z, Gu G, Chen F, et al. Targeting Irgm1 to combat osteoporosis: suppressing ROS and restoring bone remodeling. Cell Death Dis (2025). PMID: 40866352 DOI: 10.1038/s41419-025-07965-7 Source material

Publications

1 publication citing this product

  1. François A. Simard, .et al. , Oncoimmunology, 2017, 6(2): e1265716 PMID: 28344871

Added to your cart

View Cart Checkout
Loading...